Gapping up
In reaction to strong earnings/guidance:
- BIDU +9%, SINA +7.2%, EXP +6.3%, AAP +5.3%, WMT +3.9%, KSS +2%, DY +1.8%, WB +1.1%
Other news:
- ABUS +44.9% (reports "positive" follow-up data from Phase 1a/1b trial of AB-729 in chronic hepatitis B virus infection)
- DVAX +42.2% (to provide update on early-stage collaborations for COVID-19 vaccine; collaboration partner could commence Phase 1 trial as soon as July)
- DOC +7.6% (to join S&P MidCap 400)
- KRYS +2.6% (prices offering of 2,275,000 shares of its common stock at $55.00 per share)
- SDC +2.2% (files $2.8 bln lawsuit against NBC), HP +1.5% (to join the S&P SmallCap 600)
- IIVI +1.5% (believes that the Commerce Department's new rule will have no to minimal impact on the company's sales or prospects)
Analyst comments:
- WYND +6.1% (upgraded to Overweight from Neutral at JP Morgan)
- ALLO +3.1% (upgraded to Buy from Neutral at ROTH Capital)
- AYX +3.1% (upgraded to Overweight from Neutral at Piper Sandler)
- BKH +2.9% (upgraded to Outperform from Neutral at Credit Suisse)
- BYND +1.7% (initiated with a Buy at BTIG Research)
- ECHO +1.6% (upgraded to Buy from Hold at Loop Capital)
- HAIN +1.6% (upgraded to Outperform from Mkt Perform at Bernstein)
- ATCO +1.5% (upgraded to Outperform from Market Perform at BMO Capital Markets)